Scopus BioPharma Inc. (SCPS)

Scopus BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selling, General & Admin	4.08	9.03	12.61	2.73	2.23	0.41
Research & Development	5.27	2.68	15.02	7.42	0.46	0.28
Operating Expenses	9.34	11.71	27.63	10.16	2.69	0.69
Operating Income	-9.34	-11.71	-27.63	-10.16	-2.69	-0.69
Interest Expense	-	-	-0.77	-0.71	-	-
Other Non Operating Income (Expenses)	-	-	1.46	-	-	-
Pretax Income	-9.34	-11.71	-26.95	-10.86	-2.69	-0.69
Earnings From Continuing Operations	-9.34	-11.71	-26.95	-10.86	-2.69	-0.69
Minority Interest in Earnings	0.65	0.11	-	-	-	-
Net Income	-8.7	-11.61	-26.95	-10.86	-2.69	-0.69
Net Income to Common	-8.7	-11.61	-26.95	-10.86	-2.69	-0.69
Shares Outstanding (Basic)	28	21	17	13	12	11
Shares Outstanding (Diluted)	28	21	17	13	12	11
Shares Change (YoY)	41.03%	22.27%	29.11%	11.16%	13.72%	27.37%
EPS (Basic)	-0.31	-0.55	-1.56	-0.81	-0.22	-0.06
EPS (Diluted)	-0.31	-0.55	-1.56	-0.81	-0.22	-0.06
Free Cash Flow	-3.04	-8.13	-11.43	-2.53	-2.12	-0.75
Free Cash Flow Per Share	-0.11	-0.39	-0.66	-0.19	-0.18	-0.07
EBITDA	-9.34	-11.71	-27.63	-10.15	-2.69	-
D&A For EBITDA	0	0	0	0	0	-
EBIT	-9.34	-11.71	-27.63	-10.16	-2.69	-0.69

Updated Aug 11, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.